Xilio Development Inc (XLO NASDAQ) stock market data APIs
$8.5873
0.02(0.2%)
as of April 22, 2026
Try our APIs with
free plan!
Xilio Development Inc Financial Data Overview
Price chart is built with
Anychart
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Prev. Close
8.5873
Open
8.6037
High
8.6037
Low
8.3579
52 wk Range
6.468-16.52
Market Cap
49 267 K
Shares Outstanding
5 783 K
Revenue
43 766 K
EPS
0.8077
Beta
-0.12
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xilio Development Inc data using free add-ons & libraries
Get Xilio Development Inc Fundamental Data
Xilio Development Inc Fundamental data includes:
- Net Revenue: 43 766 K
- EBITDA: -40 441 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-04
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xilio Development Inc News
New
Most and least shorted small-to-mid-cap stocks
[short sale sign] Gunter_Nezhoda Short interest across small- to mid-cap stocks highlights extreme positioning at both ends, with highly speculative micro-cap names drawing heavy bearish bets, while ...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for peop...
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
An updated edition of the February 5, 2026, article. The global oncology market is entering a period of rapid evolution, fueled by rising cancer incidence, aging populations and continued scientific ...
Xilio Therapeutics Announces Pricing of Underwritten Offering
WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for peopl...
Get Xilio Development Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
